Cancer incidence and mortality are higher in blacks for almost every kind of cancer. The cancer problem in rural blacks is compounded by a regional lack of cancer specialists and treatment. The Medical College of Virginia/Community Memorial Healthcenter Minority-Based (MCV/CMH) CCOP is designed to increase the availability of protocol-based cancer treatment and control research trials to the urban and rural minorities of Richmond and Southside Virginia. Fifty percent of new cancer cases at the MCV/CMH MB-CCOP sites are minority, nearly all black. Organizational and operational plans are presented which will provide the structure for the effective implementation of multidisciplinary research. This application emphasizes the unique urban and rural populations available to the MC-CCOP, the history of extensive participation in clinical research the Medical College of Virginia Hospitals, (MCV), and MCV initiatives in cancer outreach conducted at rural MB-CCOP. The MCV/CMH MB-CCOP will collaborate with 4 research bases. MCVH has a longstanding relationship with NSABP and has won awards based on accrual and quality of data management. The CALGB affiliation, through the University of North Carolina at Chapel Hill, began in April 1989. We have an affiliation with M.D. Anderson Cancer Center, and in January 1993 joined the University of Rochester Research Center to expand the number and availability of cancer prevention and control protocols. The role of the MB-CCOP in bringing state-of-the-art treatment and cancer prevention and control studies to traditionally underserved segments of the population; urban and rural minorities is discussed and successes to date by the MCV/CMH/MB-CCOP described. The rationale for the addition of a new rural affiliate in Farmville, Virginia to assure wider participation in clinical trials is set forth, and the operational foundation for both treatment and cancer prevention and control described.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA052784-04
Application #
2094983
Study Section
Special Emphasis Panel (SRC (86))
Project Start
1990-09-01
Project End
1997-05-31
Budget Start
1994-09-15
Budget End
1995-05-31
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Ports, Katie A; Ayers, Antoinette; Crocker, Wayne et al. (2015) Community perceptions and utilization of a consumer health center. J Med Libr Assoc 103:35-9
Rafie, Carlin; Ayers, Antoinette; Cadet, Debbie et al. (2015) Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program. J Cancer Educ 30:599-606
Mosavel, Maghboeba; Rafie, Carlin; Cadet, Debbie L et al. (2012) Opportunities to reduce cancer barriers: community town halls and provider focus groups. J Cancer Educ 27:641-8
Bertagnolli, Monica M; Redston, Mark; Compton, Carolyn C et al. (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 29:3153-62
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2008) Wilms'tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-602
Silverman, Lewis R; McKenzie, David R; Peterson, Bercedis L et al. (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-903
Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8
Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6

Showing the most recent 10 out of 22 publications